Details of the Drug-Related molecule(s) Expression Atlas

General Information of Drug (ID: DMW9ZFS)

Drug Name

AIKO-150 Drug Info

Synonyms

6beta-Naltrexol; beta-Naltrexol; 6beta-Hydroxynaltrexone; 6alpha-Hydroxynaltrexone; 49625-89-0; 6alpha-Naltrexol; UNII-J0W963M37T; CHEMBL140278; J0W963M37T; naltrexol; Naltrexone-6-beta-ol; alpha-Naltrexol; 6beta-Naltrexone; 6alpha-Naltrexone; 6-alpha-naltrexol; N-Cyclopropylmethyl-7,8-dihydro-14-hydroxynorisomorphine; SCHEMBL679700; DTXSID80197942; JLVNEHKORQFVQJ-PYIJOLGTSA-N; ZINC6092289; BDBM50001709; NCGC00165851-01; FT-0672600; Opioid neutral antagonists (iv, pain), Aiko Biotechnology; 6-beta-naltrexol

Indication

Disease Entry	ICD 11	Status	REF
Opioid dependence	6C43.2Z	Phase 1	[1]

Cross-matching ID

PubChem CID: 5486554
CAS Number: CAS 49625-89-0
TTD Drug ID: DMW9ZFS

Molecule(s) Related to This Drug

Drug Therapeutic Target (DTT)

DTT Name	DTT ID	UniProt ID	MOA	REF
Opioid receptor delta (OPRD1)	TT27RFC	OPRD_HUMAN	Inhibitor	[2]
Opioid receptor kappa (OPRK1)	TTQW87Y	OPRK_HUMAN	Inhibitor	[2]
Opioid receptor mu (MOP)	TTKWM86	OPRM_HUMAN	Antagonist	[3]

------------------------------------------------------------------------------------

The Expression Level of Molecule(s) in Normal Tissue of Major ADME-Related Organs

Molecule	Molecule Type	Gene Name	Liver	Colon	Kidney	Small Intestine
Opioid receptor kappa (OPRK1)	DTT	OPRK1	5.533	5.372	5.703	5.632
Opioid receptor mu (MOP)	DTT	OPRM1	4.548	5.062	4.652	4.776
Opioid receptor delta (OPRD1)	DTT	OPRD1	2.848	2.263	1.536	2

Molecule Expression Atlas in Normal Tissue of Major ADME-related organs

The Expression Level of Molecule(s) between Disease Section and Healthy Individual Tissue

The Studied Disease

Opioid dependence

ICD Disease Classification

6C43.2Z

Molecule Name	Molecule Type	Gene Name	p-value	Fold-Change	Z-score
Opioid receptor mu (MOP)	DTT	OPRM1	5.94E-01	-0.02	-0.17
Opioid receptor delta (OPRD1)	DTT	OPRD1	5.52E-01	0.03	0.23

Molecular Expression Atlas between Disease Section and Healthy Individual Tissue

References

1	ClinicalTrials.gov (NCT00829777) Safety Study of Intravenous 6 Naltrexol (AIKO-150) in Opioid-Dependent Subjects. U.S. National Institutes of Health.
2	Syntheses and opioid receptor binding properties of carboxamido-substituted opioids. Bioorg Med Chem Lett. 2009 Jan 1;19(1):203-8.
3	Clinical pipeline report, company report or official report of signaturerx.